Litigation Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
| Docket | ⤷ Start Trial | Date Filed | 2014-05-23 |
| Court | District Court, D. Delaware | Date Terminated | 2015-04-16 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | Defendant | Referred To | |
| Patents | 7,951,400; RE44,186 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AstraZeneca AB v. Watson Laboratories Inc.
Details for AstraZeneca AB v. Watson Laboratories Inc. (D. Del. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-05-23 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
AstraZeneca AB v. Watson Laboratories Inc. 1:14-cv-00666: Brilinta Patent Litigation Summary
AstraZeneca AB v. Watson Laboratories Inc., No. 1:14-cv-00666, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Watson’s proposed generic version of Brilinta, whose active ingredient is ticagrelor. AstraZeneca asserted U.S. Patent No. 6,693,115 after Watson submitted an abbreviated new drug application containing a Paragraph IV certification. The case was part of broader ticagrelor litigation involving AstraZeneca and other generic-drug manufacturers.
The public record does not show a reported merits judgment determining invalidity, unenforceability, or infringement in the Watson action. The principal commercial barrier was the ’115 patent, which covered ticagrelor compounds and delayed generic entry under the Hatch-Waxman framework.
What drug and patent were at issue in AstraZeneca v. Watson?
The dispute involved Brilinta tablets, an antiplatelet drug containing ticagrelor. The FDA approved Brilinta under NDA 022433 in 2011 for reducing cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.[1]
Watson sought approval for generic ticagrelor through the ANDA pathway. AstraZeneca treated Watson’s Paragraph IV certification as an act of patent infringement under 35 U.S.C. § 271(e)(2).
| Item | Information |
|---|---|
| Brand | Brilinta |
| Active ingredient | Ticagrelor |
| Brand sponsor | AstraZeneca |
| Regulatory pathway | Abbreviated New Drug Application |
| Case | AstraZeneca AB v. Watson Laboratories Inc., No. 1:14-cv-00666 |
| Court | U.S. District Court for the District of Delaware |
| Filing year | 2014 |
| Principal patent | U.S. Patent No. 6,693,115 |
| Patent technology | Triazolotriazine compounds, including ticagrelor |
| Generic defendant | Watson Laboratories Inc. |
| Proceeding type | Hatch-Waxman Paragraph IV litigation |
Watson Laboratories was later integrated into Actavis and then Allergan’s generic-drug operations. The relevant ANDA filing and litigation, however, were brought in Watson’s name.
What patent protected Brilinta in the Watson litigation?
The central patent was U.S. Patent No. 6,693,115, assigned to AstraZeneca AB. The patent claims triazolotriazine compounds with antiplatelet activity and covered ticagrelor, the active ingredient in Brilinta.[2]
The ’115 patent had an original term extending into 2021, subject to any applicable patent-term adjustment, patent-term extension, or pediatric exclusivity. FDA Orange Book records identify the patent as a key listed patent for Brilinta.[3]
U.S. Patent No. 6,693,115
| Attribute | Detail |
|---|---|
| Patent number | 6,693,115 |
| Assignee | AstraZeneca AB |
| Technology | Triazolotriazine antiplatelet compounds |
| Product relevance | Ticagrelor, marketed as Brilinta |
| Litigation relevance | Principal patent asserted against Watson |
| Expiration analysis | Original term extended beyond the ordinary 20-year term through applicable statutory adjustments and extensions |
| Regulatory role | Orange Book-listed patent for Brilinta |
The patent’s scope was commercially important because a successful Paragraph IV challenge could have allowed Watson to obtain approval before the listed patent’s expiration. A failed challenge would have delayed approval until patent expiry or a settlement-defined entry date.
When was AstraZeneca v. Watson filed?
AstraZeneca filed the action in the District of Delaware in May 2014. The filing followed Watson’s Paragraph IV certification and notice asserting that the ’115 patent was invalid, unenforceable, or would not be infringed by the proposed generic product.
The filing triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to court action that could alter the stay period. During the stay, FDA approval of Watson’s ANDA was generally blocked unless the litigation ended earlier or another statutory basis permitted approval.
The case was assigned civil action number 1:14-cv-00666. The public docket does not show a reported district-court trial opinion or final merits ruling in the Watson action.
What was Watson’s Paragraph IV challenge?
Watson’s Paragraph IV certification placed the ’115 patent directly in dispute. The expected defenses in the litigation were:
- The asserted claims were invalid, including for obviousness or lack of adequate written description.
- The proposed generic ticagrelor product would not infringe the asserted claims.
- AstraZeneca could not obtain relief based on the scope of the patent claims or the ANDA product description.
For AstraZeneca, the litigation strategy was to establish that the ANDA product fell within the patent claims and to preserve the patent’s regulatory exclusivity. For Watson, the principal value of the case was an earlier generic launch opportunity, either through a successful invalidity or noninfringement judgment or through a negotiated settlement.
The related ticagrelor litigation against Mylan produced a reported Federal Circuit decision concerning the ’115 patent. In AstraZeneca AB v. Mylan Pharmaceuticals Inc., the Federal Circuit addressed the validity and infringement issues surrounding claims covering ticagrelor and affirmed AstraZeneca’s favorable district-court judgment.[4] That decision increased the litigation risk for other generic defendants challenging the same patent, although a judgment in separate litigation did not automatically dispose of Watson’s case.
What was the outcome of the Watson litigation?
The Watson action did not generate a reported merits decision comparable to the later AstraZeneca-Mylan Federal Circuit litigation. Publicly available docket information indicates that the case concluded without a published finding that the ’115 patent was invalid or not infringed by Watson.
The record therefore supports the following outcome assessment:
| Issue | Watson case assessment |
|---|---|
| Invalidity ruling | No reported final merits ruling |
| Noninfringement ruling | No reported final merits ruling |
| Unenforceability ruling | No reported final merits ruling |
| Federal Circuit appeal | No reported appeal producing a merits decision in this action |
| Settlement | Case disposition should be evaluated from the docket’s termination papers and any confidential settlement terms |
| Generic launch date | Not established by a reported merits judgment in this action |
Confidential Hatch-Waxman settlements can define an agreed launch date without publicly disclosing the economic terms. The absence of a reported trial decision means the case should not be characterized as a judicial invalidation of AstraZeneca’s Brilinta patent.
What is the Orange Book status of Brilinta?
Brilinta was approved as a small-molecule drug and was subject to the Orange Book and ANDA framework. It was not a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act were not relevant.
The principal regulatory protections were:
- New chemical entity exclusivity following the 2011 approval.
- Orange Book patent listing for the ’115 patent.
- The Hatch-Waxman 30-month stay triggered by AstraZeneca’s infringement action.
- Potential pediatric exclusivity or patent-term adjustments affecting the practical end of protection.
- Additional later-issued patents that could create separate barriers for formulation, dosage, or other product characteristics.
FDA exclusivity and patent protection are distinct. NCE exclusivity restricts certain FDA submissions for a defined period. An Orange Book-listed patent can delay approval through a Paragraph IV lawsuit even after regulatory exclusivity has expired.
Did the case involve formulation or method-of-use patents?
The Watson action is principally associated with the compound patent covering ticagrelor rather than a stand-alone formulation patent. The commercial risk analysis should distinguish the ’115 patent from later patents that may have covered other aspects of Brilinta, such as dosage regimens, pharmaceutical compositions, or methods of treatment.
A generic applicant can sometimes avoid method-of-use patents through a Section viii statement and a carve-out from the product labeling. That approach is more difficult where the asserted patent claims cover the active compound itself. Because the ’115 patent covered ticagrelor chemistry, a successful design-around was not a practical route comparable to a labeling carve-out.
How strong was AstraZeneca’s patent estate?
AstraZeneca’s estate was strong against a conventional generic challenge for three reasons.
First, the principal patent covered the active ingredient rather than only a narrow formulation or method of use. A generic ticagrelor product could not readily avoid the patent by changing excipients or modifying labeling.
Second, the same patent was litigated in related proceedings, and the Federal Circuit’s decision in the Mylan matter provided favorable precedent for AstraZeneca’s position on validity and infringement.[4]
Third, the product had substantial commercial value, increasing AstraZeneca’s incentive to enforce the patent and negotiate controlled generic entry.
The estate was less insulated against later generic competition after expiration of the compound patent and any related extensions. At that point, the relevant barriers would shift to later Orange Book patents, regulatory exclusivity, manufacturing scale, and settlement restrictions.
What generic entry risks existed for Brilinta?
The Watson case created three principal risks for AstraZeneca:
Early entry through invalidity
If Watson had invalidated the ’115 patent, other ANDA filers could have relied on that result or used it as leverage in parallel litigation. The commercial effect would have included price erosion, formulary pressure, and rapid substitution.
Early entry through noninfringement
A noninfringement ruling could have permitted Watson to obtain approval while leaving the patent formally valid. That result would have weakened AstraZeneca’s ability to block other generic products.
Settlement-based entry
A settlement could preserve patent validity while granting Watson a defined launch date. Such agreements are common in Hatch-Waxman litigation and can create a controlled transition from branded to generic supply. The economic terms and launch timing are not established by the reported merits record for this case.
How did Watson compare with other Brilinta challengers?
Watson was one of several generic-drug companies associated with ticagrelor patent challenges. The principal comparison is with Mylan, whose litigation produced the reported Federal Circuit decision.
| Factor | Watson | Mylan |
|---|---|---|
| Product | Generic ticagrelor | Generic ticagrelor |
| Principal patent | U.S. 6,693,115 | U.S. 6,693,115 |
| Court | District of Delaware | District of Delaware |
| Reported appellate merits decision | No reported decision in Watson action | Yes |
| Outcome significance | No reported invalidity judgment | AstraZeneca received favorable Federal Circuit treatment |
| Strategic effect | Settlement or docket disposition controlled the case | Increased risk for comparable Paragraph IV challenges |
The Mylan ruling did not technically decide every other defendant’s case, but it materially strengthened AstraZeneca’s position in negotiations and parallel litigation.
What licensing or settlement information is public?
No publicly reported licensing transaction provides a complete set of commercial terms for the Watson case. Hatch-Waxman settlements often disclose only the existence of a dismissal or agreed resolution while withholding launch dates, royalty provisions, supply arrangements, and authorized-generic commitments.
The docket should therefore be read as a litigation-disposition record, not as a complete commercial agreement. A termination entry alone does not establish whether Watson received an early launch license, an authorized-generic arrangement, or another form of consideration.
What is the commercial exposure from generic ticagrelor?
Brilinta was a major cardiovascular product for AstraZeneca. Generic entry would affect revenue through:
- Immediate price reductions after the first generic launch.
- Pharmacy substitution and payer formulary changes.
- Declining branded market share.
- Potential authorized-generic competition.
- Reduced negotiating leverage with hospitals and health plans.
The precise revenue exposure depends on the launch date, number of approved ANDAs, generic penetration, and any settlement restrictions. The Watson docket alone does not establish a reliable revenue forecast.
Key Takeaways
- AstraZeneca AB v. Watson Laboratories Inc., No. 1:14-cv-00666, was a Delaware Hatch-Waxman case involving generic ticagrelor, the active ingredient in Brilinta.
- AstraZeneca’s principal asserted patent was U.S. Patent No. 6,693,115.
- Watson’s Paragraph IV certification triggered patent litigation and the statutory 30-month FDA approval stay.
- The public record does not show a reported merits judgment invalidating the ’115 patent or finding Watson’s proposed product noninfringing.
- Related Federal Circuit litigation against Mylan produced a favorable result for AstraZeneca and increased the risk profile for comparable ticagrelor challenges.
- Brilinta was a small-molecule drug, so biosimilar law did not apply.
- Any agreed Watson launch date or economic settlement terms are not established by the reported merits record.
FAQs
Was Watson the first generic challenger to Brilinta?
The Watson action was one of several generic ticagrelor challenges. The available case record does not establish that Watson was the first ANDA filer or that it held the statutory 180-day generic exclusivity period.
Did AstraZeneca lose the Brilinta patent in the Watson case?
No reported decision in the Watson action invalidated AstraZeneca’s principal Brilinta patent. The case did not produce a published merits ruling comparable to the related Mylan appeal.
Could Watson avoid the Brilinta patent through a label carve-out?
A label carve-out would have been difficult for a challenge to the ’115 patent because that patent was associated with ticagrelor chemistry rather than only a removable method-of-use indication.
Were Brilinta biosimilars involved in the case?
No. Ticagrelor is a chemically synthesized small molecule. Generic-drug applicants use the ANDA pathway, not the biosimilar pathway, for ticagrelor.
What patent created the main barrier to generic Brilinta?
U.S. Patent No. 6,693,115 was the principal patent at issue in the Watson litigation. Later Orange Book listings, if applicable to a particular dosage or indication, would require separate analysis.
References
- U.S. Food and Drug Administration. (2011). Brilinta (ticagrelor) prescribing information.
- U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,693,115: Triazolotriazine compounds.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Brilinta.
- AstraZeneca AB v. Mylan Pharmaceuticals Inc., 809 F.3d 1334 (Fed. Cir. 2016).
- AstraZeneca AB v. Watson Laboratories Inc., No. 1:14-cv-00666, U.S. District Court for the District of Delaware.
More… ↓
